Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shin Nippon Biomedical Laboratories Ltd.

www.snbl.com

Latest From Shin Nippon Biomedical Laboratories Ltd.

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Financing StartUps and SMEs

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.

StartUps and SMEs Financing

Venture Funding Deals, March 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • SNBL Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Shin Nippon Biomedical Laboratories Ltd.
  • Senior Management
  • Ryoichi Nagata, MD, PhD, Pres. & CEO
  • Contact Info
  • Shin Nippon Biomedical Laboratories Ltd.
    Phone: (81) 3 5565 5001
    8-1, Akashi-cho, Chuo-ku, St. Luke's
    Tower 12F
    Tokyo, 104-0044
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register